F. Heymans

发表

Structure-activity relationships in platelet-activating factor (PAF). 11-From PAF-antagonism to phospholipase A(2) inhibition: syntheses and structure-activity relationships in 1-arylsulfamido-2-alkylpiperazines.

C. Mounier, C. Dong, C. Redeuilh, 2001, European journal of medicinal chemistry.

Structure-activity relationships in platelet activating factor. 9. From PAF-antagonism to PLA2 inhibition.

C. Mounier, C. Binisti, E. Touboul, 1997, Journal of lipid mediators and cell signalling.

Design and modeling of new platelet-activating factor antagonists. 3. Relative importance of hydrophobicity and electronic distribution in piperazinic series.

G. Dive, C. Redeuilh, A. Lamouri, 1997, Journal of lipid mediators and cell signalling.

Design and modeling of new platelet-activating factor antagonists. 2. Synthesis and biological activity of 1,4-bis-(3',4',5'-trimethoxybenzoyl)-2-alkyl and 2-alkyloxymethylpiperazines.

N. Blavet, G. Dive, A. Lamouri, 1997, Journal of lipid mediators and cell signalling.

Design of Group IIA Secreted/Synovial Phospholipase A2 Inhibitors: An Oxadiazolone Derivative Suppresses Chondrocyte Prostaglandin E2 Secretion

N. Gresh, C. Dong, J. Ombetta, 2010, PloS one.

PMS777, A Bis-interacting Ligand for PAF Receptor Antagonism and AChE Inhibition, Attenuates PAF-induced Neurocytotoxicity in SH-SY5Y Cells

C. Dong, Liang Zhu, Hongzhuan Chen, 2007, Cellular and Molecular Neurobiology.

Quantitative structure-activity relationships for N-[N',N'-disubstituted-amino)acetyl]arylamines for local anesthetic activity and acute toxicity.

F. Heymans, J. Godfroid, L. Le Thérizien, 1980, Journal of medicinal chemistry.

Biosynthesis of platelet-activating factor. I. Evidence for an acetyl-transferase activity in murine macrophages.

J. Mencia-Huerta, F. Heymans, J. Benveniste, 1982, Biochimica et biophysica acta.

Platelet activating factor (PAF‐acether): total synthesis of 1‐O‐octadecyl 2‐O‐acetyl sn‐glycero‐3‐phosphoryl choline

C. Redeuilh, F. Heymans, J. Godfroid, 1980, FEBS letters.

Effects of PAF-acether and structural analogues on platelet activation and bronchoconstriction in guinea-pigs.

B. Vargaftig, M. Chignard, C. Broquet, 1986, European journal of pharmacology.

Structural analogs of platelet-activating factor (PAF-acether).

F. Heymans, J. Godfroid, J. Benveniste, 1981, Biochimie.

New total synthesis and high resolution 1H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixtures.

F. Heymans, J. Godfroid, J. Benveniste, 1981, Biochimica et biophysica acta.

Synthesis of New Trisubstituted 4‐Aminopiperidines as PAF‐Receptor Antagonists

A. Lamouri, F. Heymans, H. Benmehdi, 2008 .

1H-and 13C-NMR studies of platelet-activating factor (PAF-acether) and analogs

F. Heymans, J. Godfroid, O. Convert, 1984 .

Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines.

Chang H. Park, A. Lamouri, F. Heymans, 2008, Bioorganic & medicinal chemistry.

PAF receptor and “cache-oreilles” effect. Simple PAF antagonists

D. Hosford, P. Braquet, G. Dive, 1991, Lipids.

Total direct chemical synthesis and biological activities of human group IIA secretory phospholipase A2.

A. Romieu, B. Roques, C. Mounier, 2002, The Biochemical journal.

Inhibition of secretory phospholipase A2. 2-Synthesis and structure-activity relationship studies of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one (PMS1062) derivatives specific for group II enzyme.

C. Dong, C. Redeuilh, J. Huet, 2005, Bioorganic & medicinal chemistry.

Design of new potent and selective secretory phospholipase A(2) inhibitors. 6-Synthesis, structure-activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives.

G. Dive, C. Redeuilh, A. Lamouri, 2010, Bioorganic & medicinal chemistry.

Preventive effects of two PAF-antagonists, PMS 536 and PMS 549, on cyclosporin-induced LLC-PK1 oxidative injury.

A. Lamouri, C. Pham-Huy, F. Heymans, 1997, Journal of lipid mediators and cell signalling.

Structure—Activity Relationships in Platelet‐Activating Factor (PAF). 11‐From PAF‐Antagonism to Phospholipase A2 Inhibition: Syntheses and Structure—Activity Relationships in 1‐Arylsulfamido‐2‐alkylpiperazines.

C. Mounier, C. Dong, C. Redeuilh, 2002 .

Structure-activity relationships on adrenoceptors and imidazoline-preferring binding sites (I(1,2)-PBSs). Part 1: Weak intramolecular H-bond and conformational flexibility in a new I1-PBS-selective imidazoline analogue, trans1-(4',5'-dihydro-1'H-imidazol-2'-yl)methyl-2-hydroxyindane (PMS 952).

G. Dive, F. Heymans, J. Godfroid, 2000, Bioorganic & medicinal chemistry.

4-Alkoxybenzamidines as new potent phospholipase A2 inhibitors.

C. Mounier, C. Binisti, F. Heymans, 1996, Biochemical pharmacology.

Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment.

Zhenguo Liu, C. Dong, J. Ombetta, 2006, Toxicology in vitro : an international journal published in association with BIBRA.

Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activity.

C. Redeuilh, C. Broquet, F. Heymans, 1987, Journal of medicinal chemistry.

Synthesis of ether phospholipids.

C. Broquet, F. Heymans, J. Godfroid, 1986, Pharmacological research communications.

Alkyl analogs of diacylglycerol as activators of protein kinase C

M. Castagna, F. Heymans, J. Godfroid, 1987, FEBS letters.

Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazines.

P. Braquet, N. Blavet, G. Dive, 1993, Journal of medicinal chemistry.

Structure-activity relationships in platelet-activating factor. Part 13: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 or pure antiretroviral activity.

G. Dive, C. Redeuilh, A. Lamouri, 2006, Bioorganic & medicinal chemistry.

Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF antagonism to inhibition of HIV-1 replication.

D. Dormont, C. Dong, C. Redeuilh, 2000, Journal of medicinal chemistry.

Protection of PMS777, a New AChE Inhibitor with PAF Antagonism, Against Amyloid-β-Induced Neuronal Apoptosis and Neuroinflammation

W. Zhou, C. Dong, W. Ding, 2009, Cellular and Molecular Neurobiology.

A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine.

Zhenguo Liu, C. Dong, J. Ombetta, 2007, International immunopharmacology.

Inhibition of secreted phospholipase A2. 4-glycerol derivatives of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one with broad activities.

G. Lambeau, C. Dong, C. Redeuilh, 2007, Journal of medicinal chemistry.

Inhibition of secretory phospholipase A2. 1-design, synthesis and structure-activity relationship studies starting from 4-tetradecyloxybenzamidine to obtain specific inhibitors of group II sPLA2s.

C. Mounier, C. Dong, A. Lamouri, 2005, European journal of medicinal chemistry.

Molecular Modeling, Design, and Synthesis of Less Lipophilic Derivatives of 3-(4-Tetradecyloxybenzyl)-4H-1,2,4-oxadiazol-5-one (PMS1062) Specific for Group II Enzyme†

N. Gresh, C. Dong, F. Chau, 2005 .

PMS-601, a New Platelet-Activating Factor Receptor Antagonist That Inhibits Human Immunodeficiency Virus Replication and Potentiates Zidovudine Activity in Macrophages

D. Dormont, A. Lamouri, F. Heymans, 2000, Antimicrobial Agents and Chemotherapy.

Macrophages Potentiates Zidovudine Activity in Immunodeficiency Virus Replication and Receptor Antagonist That Inhibits Human PMS-601 , a New Platelet-Activating Factor

A. Lamouri, F. Heymans, J. Godfroid, 2000 .

Structure-activity relationships in platelet-activating factor. Part 14: synthesis and biological evaluation of piperazine derivatives with dual anti-PAF and anti-HIV-1 activity.

G. Dive, F. Heymans, P. Clayette, 2006, Bioorganic & medicinal chemistry.

Structure-activity relationship in PAF-acether. 2. rac-1-O-Octadecyl-2-O-acetyl-3-O-[gamma-(dimethylamino)propyl]glycerol .

C. Broquet, F. Heymans, J. Godfroid, 1985, Journal of medicinal chemistry.

Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders

H. Gendelman, C. Dong, H. Gelbard, 2009, Journal of Neuroimmunology.

Novel piperazine derivative PMS1339 exhibits tri-functional properties and cognitive improvement in mice.

C. Dong, Hong-Zhuan Chen, Z. Xia, 2009, The international journal of neuropsychopharmacology.

Differential effect of PMS777, a new type of acetylcholinesterase inhibitor, and galanthamine on oxidative injury induced in human neuroblastoma SK-N-SH cells

C. Dong, Hong-Zhuan Chen, J. Ombetta, 2005, Neuroscience Letters.

Effects of a new anorectic drug (PM 170) on development of gold thioglucose-induced obesity in mice.

F. Heymans, J. Godfroid, M. Apfelbaum, 1987, General pharmacology.

A new phospholipase A2 inhibitor, unrelated to substrate analogues: kinetic characterization of the inhibition of secretory phospholipases A2 by PMS 832.

C. Mounier, C. Binisti, E. Touboul, 1997, Journal of Lipid Mediators and Cell Signalling.

PAF-receptor. 1. 'Cache-oreilles' effect of selected high-potency platelet-activating factor (PAF) antagonists.

P. Braquet, G. Dive, J. Lamotte‐Brasseur, 1989, Journal of lipid mediators.

Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders

H. Gendelman, C. Dong, H. Gelbard, 2009, Journal of Neuroimmunology.

Structure-activity relationship in PAF-acether. 4. Synthesis and biological activities of carboxylate isosteres.

C. Broquet, F. Heymans, J. Godfroid, 1988, Journal of medicinal chemistry.

A quantitative structure-activity approach to chemoreception: importance of lipophilic properties.

F. Heymans, J. Godfroid, F Heymans, 1977, Journal of theoretical biology.

Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity.

C. Dong, Hong-Zhuan Chen, F. Heymans, 2007, The international journal of neuropsychopharmacology.